Creative Planning’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $420K | Buy |
73,505
+3,264
| +5% | +$14.8K | ﹤0.01% | 3317 |
|
|
2026
Q1 | $316K | Sell |
70,241
-3,497
| -5% | -$18.2K | ﹤0.01% | 3386 |
|
|
2025
Q4 | $453K | Sell |
73,738
-3,979
| -5% | -$28.9K | ﹤0.01% | 2925 |
|
|
2025
Q3 | $562K | Buy |
77,717
+43,794
| +129% | +$260K | ﹤0.01% | 2610 |
|
|
2025
Q2 | $180K | Buy |
33,923
+9,804
| +41% | +$57.9K | ﹤0.01% | 3261 |
|
|
2025
Q1 | $214K | Buy |
24,119
+24,050
| +34,855% | +$289K | ﹤0.01% | 3009 |
|
|
2024
Q4 | $946 | Sell |
69
-9,880
| -99% | -$182K | ﹤0.01% | 3526 |
|
|
2024
Q3 | $273K | Buy |
9,949
+892
| +10% | +$24.1K | ﹤0.01% | 2599 |
|
|
2024
Q2 | $222K | Buy |
+9,057
| New | +$199K | ﹤0.01% | 2606 |
|
|
2020
Q1 | – | Sell |
-8,951
| Closed | -$244K | – | 2017 |
|
|
2019
Q4 | $244K | Buy |
8,951
+700
| +8% | +$19.3K | ﹤0.01% | 1525 |
|
|
2019
Q3 | $236K | Buy |
+8,251
| New | +$240K | ﹤0.01% | 1501 |
|
|
2019
Q2 | – | Sell |
-7,500
| Closed | -$249K | – | 2082 |
|
|
2019
Q1 | $249K | Sell |
7,500
-433
| -5% | -$13.2K | ﹤0.01% | 1444 |
|
|
2018
Q4 | $231K | Buy |
7,933
+2,150
| +37% | +$77.3K | ﹤0.01% | 1392 |
|
|
2018
Q3 | $266K | Buy |
+5,783
| New | +$257K | ﹤0.01% | 1478 |
|
|
2018
Q1 | – | Sell |
-6,894
| Closed | -$237K | – | 2086 |
|
|
2017
Q4 | $237K | Sell |
6,894
-389
| -5% | -$13.1K | ﹤0.01% | 1492 |
|
|
2017
Q3 | $263K | Buy |
7,283
+1,083
| +17% | +$30.9K | ﹤0.01% | 1417 |
|
|
2017
Q2 | $160K | Sell |
6,200
-171
| -3% | -$3.63K | ﹤0.01% | 1653 |
|
|
2017
Q1 | $122K | Buy |
6,371
+671
| +12% | +$11.9K | ﹤0.01% | 1830 |
|
|
2016
Q4 | $95K | Hold |
5,700
| – | – | ﹤0.01% | 1908 |
|
|
2016
Q3 | $117K | Hold |
5,700
| – | – | ﹤0.01% | 1742 |
|
|
2016
Q2 | $174K | Hold |
5,700
| – | – | ﹤0.01% | 1321 |
|
|
2016
Q1 | $213K | Sell |
5,700
-200
| -3% | -$7.54K | ﹤0.01% | 1176 |
|
|
2015
Q4 | $255K | Sell |
5,900
-100
| -2% | -$4.22K | ﹤0.01% | 1069 |
|
|
2015
Q3 | $225K | Buy |
+6,000
| New | +$213K | ﹤0.01% | 1129 |
|
|
2015
Q2 | – | Sell |
-6,250
| Closed | -$221K | – | 2319 |
|
|
2015
Q1 | $221K | Sell |
6,250
-2,440
| -28% | -$87.3K | ﹤0.01% | 1137 |
|
|
2014
Q4 | $296K | Buy |
8,690
+2,871
| +49% | +$102K | ﹤0.01% | 942 |
|
|
2014
Q3 | $224K | Sell |
5,819
-2,321
| -29% | -$86.6K | ﹤0.01% | 997 |
|
|
2014
Q2 | $317K | Sell |
8,140
-100
| -1% | -$3.72K | ﹤0.01% | 814 |
|
|
2014
Q1 | $282K | Buy |
8,240
+3,040
| +58% | +$94.2K | ﹤0.01% | 848 |
|
|
2013
Q4 | $109K | Hold |
5,200
| – | – | ﹤0.01% | 1152 |
|
|
2013
Q3 | $122K | Sell |
5,200
-280
| -5% | -$7.96K | ﹤0.01% | 994 |
|
|
2013
Q2 | $147K | Buy |
+5,480
| New | +$159K | ﹤0.01% | 782 |
|
Other funds holding MYGN
VPC
Creative Planning's MYGN Position: Q2 2026 in Review
Creative Planning increased its Myriad Genetics (MYGN) stake by 4.6% in Q2 2026, buying an estimated $14.8K and bringing the position to 73,505 shares worth $420K. The position accounts for ﹤0.01% of the portfolio, ranked #3317.
Creative Planning first reported a position in MYGN in Q2 2013 and has held it in 32 quarters since. The position peaked at $562K in Q3 2025. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.
- Creative Planning held 73,505 shares of Myriad Genetics worth $420K as of Q2 2026.
- Creative Planning bought 3,264 Myriad Genetics shares in Q2 2026, an estimated $14.8K.
- Myriad Genetics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3317 holding.
- Creative Planning first reported a position in Myriad Genetics in Q2 2013 and has held it in 32 quarters since.
- Creative Planning's Myriad Genetics position peaked at $562K in Q3 2025.
- 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.
Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.